News | Structural Heart | December 29, 2020

Edwards Sapien 3 TAVR Valve Receives Expanded Approval in Canada

Valve now indicated for all patients diagnosed with severe symptomatic aortic stenosis

Health Canada has approved the expanded use of the Edwards Lifesciences Sapien 3 and Sapien 3 Ultra transcatheter aortic valve replacement (TAVR) heart valves for the transfemoral treatment of patients diagnosed with severe symptomatic aortic stenosis who are at low risk for open-heart surgery. #TAVR #TAVI

December 29, 2020 — Health Canada has approved the expanded use of the Edwards Lifesciences Sapien 3 and Sapien 3 Ultra transcatheter aortic valve replacement (TAVR) heart valves for the transfemoral treatment of patients diagnosed with severe symptomatic aortic stenosis who are at low risk for open-heart surgery. 

The Sapien 3 valves are the first transcatheter aortic valve implantation (TAVI) systems to have this indication in Canada.

"Now, all Canadian patients diagnosed with aortic stenosis can be considered for TAVI with the Sapien 3 valves based on individual needs rather than risk scores," said John Webb, M.D., FRCPC, director of interventional cardiology and cardiac catheterization laboratories at St. Paul's Hospital, Vancouver, and professor of cardiology at the University of British Columbia. "Previously, their only treatment option was open-heart surgery, so this approval is particularly important for patients at low risk for surgery, whose only serious health issue may be aortic stenosis and who desire a quick return home and to their everyday activities."

The approval is based on data from the landmark PARTNER 3 Trial, an independently evaluated, randomized clinical trial, which reported a 46% lower event rate for death from any cause, stroke, or rehospitalization at 1 year after TAVI compared to open heart surgery. Patients treated with the Sapien 3 valve experienced 1% rates of death or disabling stroke at 1 year, a short length of stay and 96% discharged to home or self-care. Patients also reported significant improvements to health status and quality of life as early as 1 month after the procedure. Importantly, these findings were sustained out to 12 months post-procedure.[1] Severe aortic stenosis is a debilitating disease that often goes undiagnosed and is undertreated.

The Sapien valves are the most widely studied transcatheter valves, with more than 30,000 patients treated in clinical trials and registries in over 65 countries around the world.  Since the first commercial approval of the Sapien transcatheter valve in Europe in 2007, the Sapien family of valves have treated hundreds of thousands of patients worldwide. The Sapien 3 valves, previously approved in Canada for the treatment of both high-risk patients and intermediate-risk patients, build on Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards Sapien valves.

Reference:

1. M.J. Mack, M.B. Leon, V.H. et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients, The New England Journal of Medicine, 2019. N Engl J Med 2019; 380:1695-1705. DOI: 10.1056/NEJMoa1814052.

 

Related Content

News | Cath Lab

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

Home October 06, 2021
Home
News | Cath Lab

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device ...

Home September 21, 2021
Home
Feature | Cath Lab | By Aaron Detate and Lars Thording

In the electrophysiology (EP) lab, hundreds of thousands of used devices are sent to reprocessors every year to get ...

Home September 14, 2021
Home
News | Cath Lab

July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of ...

Home July 22, 2021
Home
News | Cath Lab

July 13, 2021 — East End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company ...

Home July 14, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal ...

Home May 14, 2021
Home
News | Cath Lab

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has ...

Home May 12, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

Home May 06, 2021
Home
Videos | Cath Lab

Ashwin Nathan M.D., a cardiology fellow in the division of Cardiovascular Medicine at the Hospital of the University of ...

Home May 05, 2021
Home
News | Cath Lab

May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for stable ...

Home May 03, 2021
Home
Subscribe Now